In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Contractile function of the right ventricle as a predictor of the effectiveness of cardiac resynchronization therapy

Session Poster session 2

Speaker Denis Lebedev

Congress : EHRA 2018

  • Topic : heart failure
  • Sub-topic : Resynchronization Therapy
  • Session type : Poster Session
  • FP Number : P820

Authors : D Lebedev (Tomsk,RU), S Popov (Tomsk,RU), S Popov (Tomsk,RU)

Authors:
D Lebedev1 , S Popov1 , S Popov1 , 1Cardiology Research Institute, Tomsk National Research Medical Center of RAS - Tomsk - Russian Federation ,

Citation:
European Heart Journal Supplements ( 2018 ) 20 ( Supplement 1 ), i150

Objective: The objective of the study was to evaluate right ventricular (RV) contractile function in patients with implanted devices for cardiac resynchronization therapy (CRT).

Materials and Methods: The study included 80 patients (49 men) with a diagnosis of dilated cardiomyopathy, mean age of 54 ± 10.5 years, heart failure (HF) functional class (FC) III by NYHA, left ventricular (LV) ejection fraction (EF) of 30.1 ± 3.8%, six-minute walk distance (6MWD) of 290.5 ± 64.3 m, and LV end-diastolic volume (EDV) of 220.7 ± 50.9 mL. Forty five patients had sustained sinus rhythm; 35 patients had chronic drug-resistant atrial fibrillation. All patients had complete blockade of the left bundle branch block; QRS duration ranged from 146 to 240 ms (183 ± 32 ms). CRT devices were implanted to all patients. In patients with persistent atrial fibrillation, complete artificial atrioventricular block was formed. In all patients, LV and RV myocardial contractile functions were assessed using equilibrium radionuclide tomoventriculography prior to CRT and 12 months after CRT device implantation.

Results: Follow-up examination was carried out after 1 year of CRT showing favorable clinical changes: HF FC decreased in all patients from III to II. 69 patients responded to CRT (86.25%); 11 patients (13.75%) did not respond to CRT. The criterion of patient’s response to CRT was LV EF increase by 15% or more within 12 months. Responders to CRT showed favorable clinical changes: LV EF increased from 30.1 ± 3.8% to 42.8 ± 4.8% (p = 0.001); LV EDV decreased from 220.7 ± 50.9 mL to 197.9 ± 47.8 mL (p = 0.005). In nonresponders, LV EF did not change significantly (30.1 ± 3.8% vs. 33.8 ± 3.8%, p = 0.001); LV EDV increased from 220.7 ± 50.9 to 227.8 ± 27.8 mL (p = 0.001). All patients were retrospectively divided into two groups: group 1 comprised patients who responded to CRT; group 2 included nonresponders. In patients of group 1, radionuclide tomoventriculography showed that RV peak filling rate (PFR) decreased from 1.8 ± 0.36 to 0.56 ± 0.16 (p = 0.001); mean diastolic filling rate (1/3FR-m) decreased from 0.6 ± 0.2 to 0.36 ± 0.15 (p = 0.001). In patients of group 2, these indices were significantly poorer (by 30% and 60%, respectively). Other parameters did not significantly differ between groups.

Conclusion: CRT in patients with severe HF was significantly more effective in those individuals who had preserved contractility of the right cardiac chambers. The values of RV PFR and RV 1/3FR-m may serve as prognostic criteria for favorable response of patients to CRT.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are